Designing studies around endpoints that truly matter to patients As Mirum’s portfolio has expanded — potentially moving into larger indications like primary sclerosing cholangitis (PSC ...

Mirum Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus ...

Itchy skin, or pruritus, can be a symptom of liver disease. However, not everyone with liver disease experiences itching, and the specific causes of this itching are unknown. Treatment for itching ...

TNF ligand superfamily member 12, CD6 isoform, and chemokine ligand 20 were associated with a higher risk of primary sclerosing cholangitis. The researchers also showed, using reverse magnetic ...

Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study ...

Biliary cirrhosis, also known as primary biliary cirrhosis, is a chronic liver ... or interfere with the bile ducts and may include: Sclerosing cholangitis is a rare chronic liver disease ...

Primary biliary cholangitis (PBC) is an autoimmune disorder that leads to the destruction of bile ducts within the liver. As more bile ducts become lost and damaged, bile acids build up within the ...

Your doctor may recommend a combination of medications, dietary supplements, and lifestyle changes to help manage primary biliary cholangitis (PBC). Some people eventually need a liver transplant ...

A copy of the R&D Day presentation can be found here. About Primary Sclerosing Cholangitis Primary Sclerosing Cholangitis (PSC) is a rare, progressive, cholestatic, immune‐mediated disease of ...

today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis (PSC), a rare and progressive liver ...

April 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary ...